{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-005369","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.661315+00:00","generated_at":"2026-06-18T21:34:47.617549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocugen reports FY2022 net loss per share $0.38; cash runway into Q1 2024; OCU400 enrollment complete","bullets":["FY2022 net loss $0.38/share vs $0.30 prior year; Q4 net loss $0.10/share vs $0.07.","Cash, equivalents, and investments $90.9M as of Dec 31, 2022; estimated runway into Q1 2024.","OCU400 Phase 1/2 RP enrollment completed; high dose set; Phase 3 targeted end of 2023.","IND submitted for OCU200 (diabetic macular edema); OCU410/OCU410ST IND planned Q2 2023.","NeoCart Phase 3 trial design agreed with FDA; start expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-005369","json":"https://secwatch.observer/filing/0001628280-23-005369.json","markdown":"https://secwatch.observer/filing/0001628280-23-005369.md","text":"https://secwatch.observer/filing/0001628280-23-005369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/ocgn-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:34:47.617549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"070922f7619bbc3eca0873f914980b2c3ef90d86","claim":"Ocugen, Inc. reported the year ended December 31, 2022 results: EPS $0.38 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.38 net loss per common share for the year ended December 31, 2022, compared to a $0.30 net loss per common share for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"EPS","value":"$0.38 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"131a8db8246defb31002ac3eac3be6a826e8310c","claim":"Ocugen, Inc. reported the three months ended December 31, 2022 results: EPS $0.10 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.10 net loss per common share for the three months ended December 31, 2022, compared to a $0.07 net loss per common share for the three months ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"EPS","value":"$0.10 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}